Enlivex (ENLV) vs Lunai Bioworks (LNAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enlivex is the larger company by market cap ($5.5 million vs $5.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | LNAI |
|---|---|---|
| Share price | $0.277 | $1.12 |
| Market cap | $5.51M | $5.08M |
| 1-day change | -10.85% | +2.75% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $494.00 | $-61.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.15 | $13.28 |
| 52-week low | $0.255 | $1.08 |
| Distance from 52-week high | -98.98% | -91.57% |
| Analyst consensus | none | — |
| Avg. price target upside | +28780.87% | — |
| Average volume | 945.30K | 181.37K |
| Shares outstanding | 19.91M | 4.53M |
| Employees | 34 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Healthcare · Biotechnology · 34 employees
About Lunai Bioworks
LNAI stock →Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC.
Healthcare · Biotechnology · 29 employees
ENLV vs LNAI FAQ
Which is bigger, Enlivex or Lunai Bioworks?
Enlivex (ENLV) is larger, with a market capitalization of $5.51M compared with $5.08M for Lunai Bioworks (LNAI).
Are Enlivex and Lunai Bioworks in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.